169 related articles for article (PubMed ID: 35091546)
1. Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.
Feng L; Chen K; Huang W; Jiang Y; Sun X; Zhou Y; Li L; Li Y; Deng X; Xu B
Cell Death Discov; 2022 Jan; 8(1):39. PubMed ID: 35091546
[TBL] [Abstract][Full Text] [Related]
2. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas.
He M; Chen K; Li S; Zhang S; Zheng J; Hu X; Gao L; Chen J; Song X; Zhang W; Wang J; Yang J
J Cancer; 2016; 7(10):1215-25. PubMed ID: 27390596
[TBL] [Abstract][Full Text] [Related]
4. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract][Full Text] [Related]
5. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
6. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
7. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
8. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Pina-Oviedo S; Bellamy WT; Gokden M
Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
[TBL] [Abstract][Full Text] [Related]
9. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
10. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
11. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.
Aukema SM; Kreuz M; Kohler CW; Rosolowski M; Hasenclever D; Hummel M; Küppers R; Lenze D; Ott G; Pott C; Richter J; Rosenwald A; Szczepanowski M; Schwaenen C; Stein H; Trautmann H; Wessendorf S; Trümper L; Loeffler M; Spang R; Kluin PM; Klapper W; Siebert R;
Haematologica; 2014 Apr; 99(4):726-35. PubMed ID: 24179151
[TBL] [Abstract][Full Text] [Related]
12. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
14. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.
Xu X; Zhang L; Wang Y; Zhang Q; Zhang L; Sun B; Zhang Y
Int J Clin Exp Pathol; 2013; 6(4):788-94. PubMed ID: 23573328
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
17. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
[TBL] [Abstract][Full Text] [Related]
18. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
[TBL] [Abstract][Full Text] [Related]
19. Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving BCL6 and MYC (Double-Hit Lymphoma).
Campuzano-Zuluaga G; Ortiz D; Peng JH; Francis Ikpatt O; Fan YS; Barredo JC; Vega F; Chapman JR
Am J Clin Pathol; 2016 May; 145(5):710-6. PubMed ID: 27124935
[TBL] [Abstract][Full Text] [Related]
20. How I treat double-hit lymphoma.
Friedberg JW
Blood; 2017 Aug; 130(5):590-596. PubMed ID: 28600333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
